| Miss Hui Lan Huang, RPH | |
|
1480 Foothill Blvd, La Verne, CA 91750-3450 | |
| (909) 593-2619 | |
| (909) 593-6789 |
| Full Name | Miss Hui Lan Huang |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1480 Foothill Blvd, La Verne, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124348537 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 42373 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Hui Lan Huang, RPH 9642 Emperor Ave, Arcadia, CA 91007-7811 Ph: (626) 574-2140 | Miss Hui Lan Huang, RPH 1480 Foothill Blvd, La Verne, CA 91750-3450 Ph: (909) 593-2619 |
News Archive
Doctations, Inc., an innovative leader in applying Internet technology to improve healthcare, today added its new Surveillance Program functionality to its groundbreaking online healthcare and medical practice management solution.
A researcher from the University of Calgary is receiving $130,000 to develop clinical decision tools to aid a physician's understanding of how a patient will respond to different treatments.
Inside U.S. Trade features an interview with HHS Assistant Secretary forAffairs Nils Daulaire, who discusses how "the department is playing a larger role than ever before in the development of U.S. trade policy, including on sensitive issues in the Trans-Pacific Partnership (TPP) negotiations like a draft proposal for a tobacco-specific 'safe harbor' and the U.S. stance on issues related to intellectual property protections for pharmaceuticals," according to the publication.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 3 days ago
Teresa Kim, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2462 Foothill Blvd, La Verne, CA 91750 Phone: 909-593-8184 Fax: 909-451-0679 | |
Chelsea Nicole White, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2143 Foothill Blvd, La Verne, CA 91750 Phone: 909-596-6168 | |
Ms. Janine N Chen, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2143 Foothill Blvd, La Verne, CA 91750 Phone: 909-596-6168 Fax: 909-596-6155 | |
Vipul Bhavani, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1480 Foothill Blvd, La Verne, CA 91750 Phone: 909-593-2619 | |
Mr. John Tuong Ngo, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1479 Foothill Blvd, La Verne, CA 91750 Phone: 909-593-7534 | |
Dr. Calvin Yiu Lee, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1023 Hormel Ave, La Verne, CA 91750 Phone: 909-919-4414 |